LLYX250117P13000
- 0.00
- 0.000.00%
Defiance Daily Target 2X Long LLY ETF Newsroom
Lilly Signs Licensing Deal With Mediar for IPF Drug
"Eli Lilly In Advanced Talks To Buy U.S. Cancer Biotech For Up To $2.5B; Scorpion's Drug Candidate Inhibits A Mutation That Is A Major Driver Of Breast, Gynaecological And Head And Neck Cancers" - Financial Times
HIMS Downgraded, Agilon Upgraded at Citi in 2025 Health Tech Review
On Thursday, Alchemab Therapeutics Entered A Collaboration With Eli Lilly To Discover, Develop, And Commercialize Up To Five Therapeutics For Amyotrophic Lateral Sclerosis; Alchemab Will Receive An Undisclosed Upfront Payment And Is Eligible To...
Morgan Stanley's outlook for the top ten investment trends in 2025: the revival of nuclear energy, the AI revolution in the financial Industry, quantum computing, oral weight loss medications...
Morgan Stanley pointed out that historically, popular themes with strong profit momentum tend to have a strong sustainability, such as AI, defense spending, and obesity drugs; negative prices and quantum computing are expected to emerge as new investment hotspots.
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
'Medicare Can Now Cover Eli Lilly's Zepbound For Sleep Apnea, CMS Says' - CNBC
These Stocks Are Expected to See at Least 25% Revenue Growth in 2025 – Wolfe
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not
Eli Lilly's Options: A Look at What the Big Money Is Thinking
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Healthcare Sector's 2024 Gainers and Losers: Intuitive Surgical, Boston Scientific Tops Chart
Israel Englander's Millennium Management Dumps Nvidia, Loads Up On Broadcom — Here's What The $70 Billion Hedge Fund Sees
Novo Nordisk Seeks to Block Compounded Victoza
Smart Money Is Betting Big In LLY Options
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer